Eric Jonasch, MD, discusses the mechanism of action of NKT-2152.
Eric Jonasch, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the mechanism of action of a novel, potent, selective orally available HIF-2α inhibitor called NKT-2152.
Currently, NKT-2152 is being investigated in an ongoing, multicenter, first-in-human, phase 1/2 trial (NCT05119335) for the potential treatment of patients with previously treated advanced clear cell renal cell carcinoma (ccRCC). Adult patients with advanced ccRCC who have an ECOG performance status of 0-2 and measurable disease per RECIST 1.1 are eligible for enrollment in the study. Patients treated previously with HIF2a inhibitors, require supplemental oxygen, and those with significant cardiac disease are excluded from the study.
Jonasch presented preliminary data from the phase 1/2 study during an oral presentation at the ESMO 2024 Congress.
Transcription:
0:09 | NKT-2152 is a HIF-2α inhibitor, so it will bind to HIF-2α to prevent heterodimerization with HIF-1 beta. And this is important when you lose VHL function, which happens in a lot of clear cell renal cell carcinomas, because then you get unbridled transcription of these HIF-2α client genes, which is oncogenic.
0:32 | So, it is similar to an approved agent called belzutifan [Welireg]. It is different from [tyrosine kinase inhibitors (TKIs)]. TKIs typically are VEGF receptor inhibitors, and so that would be a considerably downstream sort of effect of having HIF-2α upregulation. So, this is kind of getting upstream and closer to the source, if you will.
Long-Term Data Prompt Shifting Approaches to Frontline RCC Therapy
October 8th 2024During a Case-Based Roundtable® event, Chandler Park, MD, moderated a discussion on how recent trial data and sites of metastasis affect treatment of favorable-risk metastatic clear cell renal cell carcinoma in the second article of a 2-part series.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
Single CAR-T Infusion Shows Deep and Durable Responses in Relapsed Myeloma
October 2nd 2024A single infusion of the autologous GPRC5D-targeted CAR T-cell therapy BMS-986393 led to high response rates in patients with relapsed/refractory multiple myeloma who received between 1 and 3 prior lines of therapy.
Read More